I 

117TH CONGRESS 

1ST SESSION H. R. 2007 

To provide for research and education with respect to uterine fibroids, and 

for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 18, 2021 

Ms. CLARKE of New York (for herself, Ms. KELLY of Illinois, Mrs. WATSON

COLEMAN, and Mr. DAVID SCOTT of Georgia) introduced the following 

bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To provide for research and education with respect to uterine 

fibroids, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stephanie Tubbs Jones 

5 Uterine Fibroid Research and Education Act of 2021’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds as follows: 

8 (1) It is estimated that 20 percent to 50 per9 cent of women of reproductive age currently have 


pbinns on DSKJLVW7X2PROD with BILLS
2 

•HR 2007 IH

1 uterine fibroids, and up to 77 percent of women will 

2 develop fibroids before menopause. 

3 (2) In the United States, an estimated 

4 26,000,000 women between the ages of 15 and 50 

5 have uterine fibroids, and approximately 15,000,000 

6 of these individuals experience symptoms. Uterine 

7 fibroids may cause significant morbidity through 

8 their presence in the uterus and pelvic cavity, and 

9 symptoms can include pelvic pain, several menstrual 

10 bleeding, iron-deficiency anemia, fatigue, bladder or 

11 bowel dysfunction, infertility, and pregnancy com12 plications and loss. 

13 (3) The pain, discomfort, stress, and other 

14 physical and emotional symptoms of living with 

15 fibroids may significantly interfere with a woman’s 

16 quality of life, compromising her ability to function 

17 normally or work or care for her family, and may 

18 lead to more severe health and wellness issues. 

19 (4) Most women will experience uterine fibroids 

20 by the age of 50, yet few data exist describing the 

21 overall patient experience with fibroids. 

22 (5) Many people with fibroids are likely 

23 undiagnosed. Patients wait on average 3.6 years be24 fore seeking treatment, and over 40 percent of pa25 tients see two or more health care providers prior to 


pbinns on DSKJLVW7X2PROD with BILLS
3 

•HR 2007 IH

1 receiving a diagnosis, underscoring the need for im2 proved awareness and education. 

3 (6) People of color are more likely to develop 

4 uterine fibroids. It is estimated that more than 80 

5 percent of Black women and about 70 percent of 

6 white women develop fibroids by the time they reach 

7 menopause. Black individuals with fibroids have also 

8 been shown to have more severe symptoms and de9 velop early-onset uterine fibroids that develop into 

10 larger tumors. 

11 (7) Current research and available data do not 

12 provide adequate information on the prevalence and 

13 incidence of fibroids in Asian, Hispanic, and Black 

14 individuals. 

15 (8) Symptomatic uterine fibroids can cause re16 productive problems, including infertility. People 

17 with uterine fibroids are much more likely to mis18 carry during early pregnancy than people without 

19 them. 

20 (9) According to the Evidence Report Summary 

21 on the Management of Uterine Fibroids, as compiled 

22 by the Agency for Healthcare Research and Quality 

23 of the Department of Health and Human Services, 

24 there is a ‘‘remarkable lack of high-quality evidence 


pbinns on DSKJLVW7X2PROD with BILLS
4 

•HR 2007 IH

1 supporting the effectiveness of most interventions for 

2 symptomatic fibroids’’. 

3 (10) Most medical options for managing fibroid 

4 symptoms regulate or suppress menstruation and 

5 prevent pregnancy. There is a great need for mini6 mally invasive, fertility-friendly therapies, as well as 

7 biomarkers, imaging assessments, or risk-based algo8 rithms that can help predict patient response to 

9 therapy. 

10 (11) The presence of symptomatic uterine 

11 fibroids is the most common reason for 

12 hysterectomies, accounting for 39 percent of 

13 hysterectomies annually in the United States. Ap14 proximately 42 per 1,000 women are hospitalized 

15 annually because of uterine fibroids, but Black pa16 tients have higher rates of hospitalization, 

17 hysterectomies, and myomectomies compared to 

18 white women. Uterine fibroids are also the leading 

19 cause of hospitalization related to a gynecological 

20 disorder. 

21 (12) The personal and societal costs of uterine 

22 fibroids in the United States are significant. Uterine 

23 fibroid tumors have been estimated to cost the 

24 United States $5,900,000,000 to $34,400,000,000 

25 annually. The annual direct costs, including surgery, 


pbinns on DSKJLVW7X2PROD with BILLS
5 

•HR 2007 IH

1 hospital admissions, outpatient visits, and medica2 tions, were estimated at $4,100,000,000 to 

3 $9,400,000,000 annually. Estimated lost work-hour 

4 costs ranged from $1,550,000,000 to 

5 $17,200,000,000 annually. Obstetric outcomes that 

6 were attributed to fibroid tumors resulted in costs of 

7 $238,000,000 to $7,760,000,000 annually. 

8 (13) At the federal level, uterine fibroid re9 search remains drastically underfunded as compared 

10 to patient disease burden. In 2019, fibroid research 

11 received about $17,000,000 in funding from the Na12 tional Institutes of Health, putting it in the bottom 

13 50 of 292 funded conditions. 

14 SEC. 3. RESEARCH WITH RESPECT TO UTERINE FIBROIDS. 

15 (a) RESEARCH.—The Secretary of Health and 

16 Human Services (referred to in this Act as the ‘‘Sec17 retary’’) shall expand, intensify, and coordinate programs 

18 for the conduct and support of research with respect to 

19 uterine fibroids. 

20 (b) ADMINISTRATION AND COORDINATION.—The 

21 Secretary shall carry out the conduct and support of re22 search pursuant to subsection (a), in coordination with the 

23 appropriate institutes, offices, and centers of the National 

24 Institutes of Health and any other relevant Federal agen25 cy, as determined by the Director. 


pbinns on DSKJLVW7X2PROD with BILLS
6 

•HR 2007 IH

1 (c) AUTHORIZATION OF APPROPRIATIONS.—For the 

2 purpose of carrying out this section, there are authorized 

3 to be appropriated $30,000,000 for each of fiscal years 

4 2022 through 2026. 

5 SEC. 4. RESEARCH WITH RESPECT TO MEDICAID COV6 ERAGE OF UTERINE FIBROIDS TREATMENT. 

7 (a) RESEARCH.—The Secretary (or the Secretary’s 

8 designee) shall establish a research database, or expand 

9 an existing research database, to collect data on services 

10 furnished to individuals diagnosed with uterine fibroids 

11 under a State plan (or a waiver of such a plan) under 

12 the Medicaid program under title XIX of the Social Secu13 rity Act (42 U.S.C. 1396 et seq.) or under a State child 

14 health plan (or a waiver of such a plan) under the Chil15 dren’s Health Insurance Program under title XXI of such 

16 Act (42 U.S.C. 1397aa et seq.) for the treatment of such 

17 fibroids for purposes of assessing the frequency at which 

18 such individuals are furnished such services. 

19 (b) REPORT.— 

20 (1) IN GENERAL.—Not later than the date that 

21 is two years after the date of the enactment of this 

22 Act, the Secretary shall submit to Congress a report 

23 on the amount of Federal and State expenditures 

24 with respect to services furnished for the treatment 

25 of uterine fibroids under State plans (or waivers of 


pbinns on DSKJLVW7X2PROD with BILLS
7 

•HR 2007 IH

1 such plans) under the Medicaid program under such 

2 title XIX and State child health plans (or waivers of 

3 such plans) under the Children’s Health Insurance 

4 Program under such title XXI. 

5 (2) COORDINATION.—The Secretary shall co6 ordinate the development and submission of the re7 port required under paragraph (1) with any other 

8 relevant Federal agency, as determined by the Sec9 retary. 

10 SEC. 5. EDUCATION AND DISSEMINATION OF INFORMATION 

11 WITH RESPECT TO UTERINE FIBROIDS. 

12 (a) UTERINE FIBROIDS PUBLIC EDUCATION PRO13 GRAM.—The Secretary shall develop and disseminate to 

14 the public information regarding uterine fibroids, includ15 ing information on— 

16 (1) the awareness, incidence, and prevalence of 

17 uterine fibroids among individuals, including all mi18 nority individuals; 

19 (2) the elevated risk for minority individuals to 

20 develop uterine fibroids; and 

21 (3) the availability, as medically appropriate, of 

22 the range of treatment options for symptomatic 

23 uterine fibroids, including non-hysterectomy treat24 ments and procedures. 


pbinns on DSKJLVW7X2PROD with BILLS
8 

•HR 2007 IH

1 (b) DISSEMINATION OF INFORMATION.—The Sec2 retary may disseminate information under subsection (a) 

3 directly or through arrangements with intra-agency initia4 tives, nonprofit organizations, consumer groups, institu5 tions of higher education (as defined in section 101 of the 

6 Higher Education Act of 1965 (20 U.S.C. 1001)), or Fed7 eral, State, or local public private partnerships. 

8 (c) AUTHORIZATION OF APPROPRIATIONS.—For the 

9 purpose of carrying out this section, there are authorized 

10 to be appropriated such sums as may be necessary for 

11 each of fiscal years 2022 through 2026. 

12 SEC. 6. INFORMATION TO HEALTH CARE PROVIDERS WITH 

13 RESPECT TO UTERINE FIBROIDS. 

14 (a) DISSEMINATION OF INFORMATION.—The Sec15 retary of Health and Human Services shall, in consulta16 tion and in accordance with guidelines from relevant med17 ical societies, work with health care-related specialty soci18 eties and health systems to promote evidence-based care 

19 for individuals with fibroids. Such efforts shall include mi20 nority individuals who have an elevated risk to develop 

21 uterine fibroids and the range of available options for the 

22 treatment of symptomatic uterine fibroids, including non23 hysterectomy drugs and devices approved under the Fed24 eral Food, Drug, and Cosmetic Act. 


pbinns on DSKJLVW7X2PROD with BILLS
9 

•HR 2007 IH

1 (b) AUTHORIZATION OF APPROPRIATIONS.—For the 

2 purpose of carrying out this section, there are authorized 

3 to be appropriated such sums as may be necessary for 

4 each of the fiscal years 2022 through 2026. 

5 SEC. 7. DEFINITION. 

6 In this Act, the term ‘‘minority individuals’’ means 

7 individuals who are members of a racial and ethnic minor8 ity group, as defined in section 1707(g) of the Public 

9 Health Service Act (42 U.S.C. 300u–6(g)). 

Æ 


pbinns on DSKJLVW7X2PROD with BILLS